What is the overall financial performance of Intuitive Surgical for the third quarter of 2014?

In the third quarter of 2014, Intuitive Surgical reported a 10% increase in total revenue to $550.1 million, driven by higher system shipments and recurring revenue. However, operating income saw a 9% decrease compared to the prior year quarter, primarily due to increased operating expenses.

What is the significance of the new da Vinci Xi Surgical System launch?

The launch of the da Vinci Xi Surgical System in the second quarter of 2014 marks the introduction of the company's fourth-generation platform. This new system is designed for a wider range of procedures, including multi-quadrant surgeries, and features an improved overhead instrument arm architecture, enhanced visualization, and more flexible instrument arms, aiming to broaden market reach and adoption.

What are the key litigation and regulatory risks the company is facing?

Intuitive Surgical is involved in ongoing product liability litigation, with a substantial number of claims related to its instruments. The company recorded a significant charge in 2014 related to these claims. Additionally, it faces regulatory scrutiny, including FDA inspections and reporting requirements for device malfunctions and adverse events. While the company believes it is addressing these matters, they pose a potential risk to financial performance and reputation.

How is the company managing its cash and investments?

As of September 30, 2014, Intuitive Surgical held $2.3 billion in cash, cash equivalents, and investments. The company utilized $1.0 billion for share repurchases during the nine-month period. Despite the decrease from the end of 2013, management believes its liquidity position is sufficient to fund future growth and operations.

ISRG 10-Q Quarterly Report Q3 FY2014 — Revenue, Net Income, EPS

Summary

Intuitive Surgical, Inc. (ISRG) reported its third-quarter 2014 financial results, showing a 10% increase in total revenue to $550.1 million, driven by higher system shipments and recurring service revenue. While overall revenue showed year-over-year growth, the nine-month period saw a decrease primarily due to lower system sales, partially offset by increased recurring revenue, which now constitutes 73% of total revenue for this period. The company also launched its new da Vinci Xi Surgical System, aiming to broaden its product offerings and address diverse surgical needs. Despite revenue growth, operating income decreased by 9% year-over-year for the quarter, impacted by increased selling, general, and administrative expenses, including costs related to establishing a direct sales organization in Japan and higher legal expenses. The company is facing ongoing product liability litigation, for which it recorded a significant pre-tax charge in the first half of 2014. Management believes the company has sufficient liquidity for future operations.

Financial Highlights

46 data points

Beta

Revenue

$550.10M

0.7% Gross Margin

Net Income

$123.70M

0.2% Net Margin

EPS (Diluted)

$0.37

Total Assets

$3.65B

Cash & Equivalents

$493.00M

Free Cash Flow

$150.60M

Financial Statements

Beta

Revenue	$550.10M
Cost of Revenue	$189.50M
Gross Profit	$360.60M
R&D Expenses	$47.50M
SG&A Expenses	$154.00M
Operating Expenses	$201.50M
Operating Income	$159.10M
Net Income	$123.70M
EPS (Basic)	$0.38
EPS (Diluted)	$0.37
Shares Outstanding (Basic)	324.90M
Shares Outstanding (Diluted)	332.10M

Key Highlights

1Total revenue for the third quarter of 2014 increased by 10% to $550.1 million compared to the same period in 2013, driven by increased system shipments and recurring revenue.
2Recurring revenue (instruments, accessories, and service) represented 69% of total revenue in Q3 2014, up from 68% in Q3 2013, highlighting the increasing importance of this segment.
3The company launched its fourth-generation da Vinci Xi Surgical System in Q2 2014, which is expected to enhance its product portfolio and address a wider range of surgical procedures.
4Despite revenue growth, operating income decreased by 9% year-over-year in Q3 2014, impacted by higher SG&A expenses and legal costs.
5The company recorded a $77.0 million pre-tax charge in the first nine months of 2014 related to estimated product liability claims, with $56.7 million accrued as of September 30, 2014.
6Cash, cash equivalents, and investments decreased by $491.2 million from December 31, 2013, to $2.3 billion as of September 30, 2014, largely due to a $1.0 billion share repurchase program.
7Installed base of da Vinci Surgical Systems grew to 3,174 units as of September 30, 2014.

INTUITIVE SURGICAL INC Quarterly Report for Q3 Ended Sep 30, 2014

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions